Antitumor effects of erlotinib in combination with berberine in A431 cells

BACKGROUND: First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib, have been shown to target tumors with L858R (exon 21) and exon 19 deletions, resulting in significant clinical benefits. However, acquired resistance often occurs due to EGFR muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuan, Xiangdan, Yang, Xingying, Zhu, Weiwei, Zhao, Yue, Luo, Rui, Huang, Yanping, Wang, Xuanjun, Sheng, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173514/
https://www.ncbi.nlm.nih.gov/pubmed/37170144
http://dx.doi.org/10.1186/s40360-023-00661-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173514/
https://www.ncbi.nlm.nih.gov/pubmed/37170144
http://dx.doi.org/10.1186/s40360-023-00661-2

Ejemplares similares